SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

Deep-pocketed investors have adopted a bearish approach towards DexCom (NASDAQ:DXCM), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

DexCom (NASDAQ: DXCM) is not a stock that investors should be rushing to sell. It has a few different opportunities to continue pursuing to generate growth, it has plenty of recurring revenue, and the ...

Many pharmaceutical companies are looking to develop and market the now highly popular GLP-1 drugs, which help treat diabetes, help patients lose weight, and reduce their risk of a range of conditions ...

Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...

Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q4 patient ...

DexCom's stock crashed after the company lowered its guidance last quarter. The rationale for the adjustment was a bit concerning, prompting analysts to wonder if there are greater problems facing the ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

If you are wondering whether DexCom's current share price lines up with its underlying worth, or if the market is mispricing the stock, this article walks through that question step by step. DexCom ...

Dexcom’s first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University’s ...